Partners & Funding

    Consortium

    The development of gene therapy for rare bleeding disorders is a collaboration between the research group of Prof. dr. Jan Voorberg of Sanquin Research, Prof. dr. Joost Verhaagen of The Netherlands Institute of Neuroscience and SanaGen.

     

    Prof. dr. Jan Voorberg, head of the Molecular and Cellular Hemostasis research group at Sanquin, is an internationally recognized expert in the field of bleeding disorders who has extensively studied rare bleeding disorders such as hemophilia and other blood clotting factor deficiencies. He is a top global specialist in the field of rare bleeding disorders.

     

    Prof. dr. Joost Verhaagen and his research group perform basic and translational research with the aim to advance the field of restorative neuroscience and neurology. He is an expert on gene therapy, with decades of research experience in the field. His group focuses on the cellular and molecular mechanisms that underly degeneration, regeneration and plasticity of the central and peripheral nervous system. Adeno-associated viral vectors (AAV) and lentiviral vectors (LV) are used at this lab to target the nervous system, another collaboration area with SanaGen.

     

    From left to right:
    Prof. Dr. Joost Verhaagen (NIN), Dr. David Mosmuller (SanaGen), Prof. Dr. Jan Voorberg (Sanquin)

    Funding

    The development of gene therapy for Rare Bleeding Disorders, also known as the RBD-Cure project, is a collaboration project between the research group of Prof. dr. Jan Voorberg of Sanquin Research, Prof. dr. Joost Verhaagen of The Netherlands Institute of Neuroscience and SanaGen. This collaboration project is co-funded by the PPP Allowance made available by Health~Holland, Top Sector Life Sciences & Health, to stimulate public-private partnerships. Top Sector Life Sciences & Health (LSH) supports innovative research and development realized by public-private partnerships (PPPs) of the Dutch LSH sector. The Top Sector brings together stakeholders in a shared, consolidated innovation infrastructure. By means of PPP Allowance, the Top Sector provides a financial instrument to help consortia consisting of research organizations, knowledge institutes, companies, and health foundations to realize their innovative ideas.

    For more information please visit: https://www.health-holland.com/calls/tki-match

    Prior to the RBD-Cure project the collaboration between Sanquin, The Netherlands Institute of Neuroscience and SanaGen started with the X-Cure project, developing gene therapy for factor X deficiency. This project was also co-funded by the PPP Allowance made available by Health~Holland, Top Sector Life Sciences & Health. The RBD-Cure project is a continuation of the X-Cure project with the objective to develop an affordable gene therapy platform for RBDs which can also improve the expression of our FX gene therapy product as well being applied to other rare bleeding disorders.

    Furthermore, SanaGen has received a convertible loan from the Noord-Holland Innovation Fund for the development of gene therapy for rare bleeding disorders. The Noord-Holland Innovation Fund is an initiative of the Dutch province of Noord-Holland, University of Amsterdam, Amsterdam University of Applied Sciences, Amsterdam UMC, and Sanquin, with support from the European Union through the European Regional Development Fund. The Innovation Fund supports entrepreneurs in the Dutch province of Noord-Holland by financing innovation in the Proof-of-Concept phase by providing convertible loans.

    SanaGen: one step closer to a cure for genetic disorders